Revive Therapeutics (XCNQ:RVV) Total Stockholders Equity : C$6.40 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics Total Stockholders Equity?

Revive Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was C$6.40 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Revive Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was C$0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Revive Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

Revive Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Revive Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Total Stockholders Equity Chart

Revive Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Stockholders Equity

Get a 7-Day Free Trial

7.43

28.81

12.60

10.65

7.23

Revive Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															9.53	9.82	7.23	6.76	6.40

Revive Therapeutics (XCNQ:RVV) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Revive Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(6.395	-	0)	/	418.564
	=	0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Revive Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	6.395
	=	0.00

Revive Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Revive Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RVVTF:USA 31R:Germany

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1

Website

https://www.revivethera.com

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

Executives

Michael Frank	Director, Senior Officer
Derrick Alexander Welsh	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)

Revive Therapeutics Headlines

No Headlines